title: Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
abstract: OBJECTIVE
  It is widely believed that persistent Mycobacterium tuberculosis inhabits necrotic lung granulomas in humans and that the microenvironmental conditions encountered therein render the bacilli phenotypically tolerant to antibiotics, accounting for the long duration required for successful treatment of tuberculosis (TB). To validate this belief, we directly compared the activity of rifampicin/isoniazid/pyrazinamide (RHZ) against chronic TB infection in guinea pigs, which exhibit caseous granulomas histologically resembling human caseous foci, and in mice, which lack necrotic granulomas.
  
  
  METHODS
  Guinea pigs and mice were aerosol-infected with M. tuberculosis CDC1551 and twice weekly treatment with RHZ was started 4 weeks later. Culture-positive relapse was assessed in subgroups of guinea pigs after 3 months and 4 months of treatment.
  
  
  RESULTS
  All guinea pig lungs exhibited histological evidence of granulomas with central caseation, while mouse lungs exhibited cellular lesions at the initiation of antibiotic treatment. Guinea pig lungs became culture-negative after 2 months of RHZ given twice weekly at human-equivalent doses. Relapse rates in guinea pigs were 0% (0/10) both after 3 months and 4 months of treatment. In contrast, all mouse lungs remained culture-positive after 4 months of equivalent RHZ exposures.
  
  
  CONCLUSIONS
  Caseous necrosis does not reduce the sterilizing activity of the standard antituberculosis regimen of RHZ. Our findings have important implications for the use of alternative animal models in testing novel TB drug regimens and for modelling M. tuberculosis persistence.
authors: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors: Zahoor
authors: Z
authors: Ahmad
authors: Mostafa M
authors: MM
authors: Fraig
authors: Michael L
authors: ML
authors: Pinn
authors: Sandeep
authors: S
authors: Tyagi
authors: Eric L
authors: EL
authors: Nuermberger
authors: Jacques H
authors: JH
authors: Grosset
authors: Petros C
authors: PC
authors: Karakousis
references: J Exp Med. 1956 Nov 1;104(5):763-802
references: 13367342
references: Antimicrob Agents Chemother. 2007 Sep;51(9):3338-45
references: 17517834
references: Open Infect Dis J. 2008 Dec;2:59-76
references: 23814629
references: J Antimicrob Chemother. 2010 Oct;65(10):2172-5
references: 20693172
references: Am Rev Tuberc. 1952 May;65(5):519-22
references: 14924174
references: Vaccine. 2005 Feb 3;23(11):1393-8
references: 15661388
references: J Pathol. 2006 Nov;210(3):298-305
references: 17001607
references: Antimicrob Agents Chemother. 2001 Dec;45(12):3631-4
references: 11709357
references: Antimicrob Agents Chemother. 2011 Apr;55(4):1527-32
references: 21282447
references: Nature. 1970 Jul 11;227(5254):138-40
references: 4393335
references: J Infect Dis. 2008 Jul 15;198(2):275-83
references: 18491971
references: J Antimicrob Chemother. 2008 Feb;61(2):323-31
references: 18156607
references: Am Rev Tuberc. 1954 Aug;70(2):367-9
references: 13180876
references: Cell Microbiol. 2006 Feb;8(2):218-32
references: 16441433
references: Am J Respir Cell Mol Biol. 2008 Apr;38(4):455-62
references: 18032570
references: Int J Tuberc Lung Dis. 2003 Jan;7(1):6-21
references: 12701830
references: Br J Exp Pathol. 1961 Feb;42:83-8
references: 13740304
references: Gene Ther. 2005 Apr;12(7):634-8
references: 15690060
references: Am Rev Respir Dis. 1989 Apr;139(4):871-6
references: 2648911
references: Am Rev Respir Dis. 1965 Nov;92(5):687-703
references: 5321145
references: Antimicrob Agents Chemother. 2011 Jan;55(1):124-31
references: 20937788
references: Antimicrob Agents Chemother. 2004 Jan;48(1):340-3
references: 14693563
references: Antimicrob Agents Chemother. 2009 Aug;53(8):3197-204
references: 19451303
references: Antimicrob Agents Chemother. 2003 Jul;47(7):2118-24
references: 12821456
references: J Infect Dis. 2008 Jun 1;197(11):1493-8
references: 18426366
references: Trends Mol Med. 2001 Mar;7(3):135-7
references: 11286786
references: Am J Med Sci. 1956 Jul;232(1):30-7; passim
references: 13326887
references: J Infect Dis. 2009 Oct 1;200(7):1136-43
references: 19686043
references: Antimicrob Agents Chemother. 2010 May;54(5):1820-33
references: 20160055
references: Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14
references: 20049645
references: Antimicrob Agents Chemother. 2004 Aug;48(8):2951-7
references: 15273105
references: J Antimicrob Chemother. 2010 Apr;65(4):729-34
references: 20123722